This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

collagenase Clostridium histolyticum (Xiapex®)

Reference No. 912

Publication date:

Appraisal information

collagenase Clostridium histolyticum (Xiapex®) 0.9 mg powder and solvent for solution for injection

Company: Swedish Orphan Biovitrum Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/06/2015

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, collagenase Clostridium histolyticum (Xiapex®) cannot be endorsed for use within NHS Wales for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
Statement of Advice (SOA)